Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Breast Neoplasms

erlotinib hydrochloride has been researched along with Breast Neoplasms in 95 studies

Research

Studies (95)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's36 (37.89)29.6817
2010's48 (50.53)24.3611
2020's11 (11.58)2.80

Authors

AuthorsStudies
Aronis, C; Chaniotis, D; Degn, SE; Frantzi, T; Kalofonos, HP; Koutras, A; Makatsoris, T; Papanastasiou, AD; Sirinian, C1
Abdel-Aziz, HA; Abdelmoaz, MA; Al-Warhi, T; Albohy, A; Aljaeed, N; El Kerdawy, AM; Eldehna, WM; Elkaeed, EB; Elsayed, ZM; Said, MA1
Alwanian, WM; Bie, W; Kajdacsy-Balla, A; Tyner, AL; Vlajic, K1
Acconcia, F1
Chu, J; Do, SI; Jung, US; Kim, DH; Kim, HS; Kwon, MJ; Min, KW; Son, BK1
Abdel-Ghany, S; Alqosaibi, AI1
Broude, EV; Kassler, S; Lim, CU; McDermott, MSJ; Melendez, T; Munie, J; Sharko, AC1
Eichenfield, DZ; Orme, CM; Seidman, JS1
Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM1
Copur, MS; Faris, S; Horn, AJ; Lackner, R; Rodriguez, P; Zusag, T1
Eissa, AAM; Fahim, SH; Gamal, MA; Nissan, YM; Ragab, FA; Salem, MA1
Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E1
Chen, J; Chen, Q; Liang, C; Liu, Z; Xu, L; Yang, Y; Yang, Z1
Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL1
Turki, T; Wang, JTL; Wei, Z1
Guan, S; Ji, G; Yao, X; Zhang, C1
Astashchanka, A; Jacobsen, BM; Shroka, TM1
Baniasadi, SP; Bassi, C; Berger, T; Cappello, P; Cassetta, L; Cescon, DW; Chu, MF; Duncan, G; Göbl, C; Gorrini, C; Haight, J; Herranz, C; Jafari, SM; Jones, L; Kubli, SP; Lazaro, C; Lindzen, M; Mak, TW; Palomero, L; Petit, A; Pettersson, S; Pollard, JW; Pujana, MA; Ramachandran, P; Roux, C; Silvester, J; Snow, B; Soong, D; Thu, KL; Tinto, P; Wakeham, A; Yarden, Y; Zhou, W1
He, Y; Li, M; Li, Y; Tan, Z; Tu, S; Yang, J; Zhang, L; Zhou, W; Zhou, X1
Bingman, A; Carothers, S; Kraut, EH; Layman, RM; Lustberg, MB; Lynn, M; Mrozek, E; Ottman, S; Ramaswamy, B; Reinbolt, R; Ruppert, AS; Shapiro, CL; Wesolowski, R1
Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W1
Augustin, A; Avila, D; Berrera, M; Ebeling, M; Golling, S; Lamerz, J; Langen, H; Tzouros, M1
Bobilev, D; Peleg, R; Priel, E1
Yaqub, F1
Choi, JS; Choi, YL; Jung, K; Kim, YJ; Kundu, J; Kwon, MJ; Lee, SE; Oh, E; Seo, J; Shin, YK; Song, JY1
Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W1
Beißbarth, T; Bender, C; Henjes, F; Korf, U; Sonntag, J; von der Heyde, S1
Calcasola, M; Cane, P; Izatt, L; Michalarea, V; Spicer, J; Tobal, K1
Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M1
Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T1
Haskins, JW; Nguyen, DX; Stern, DF1
Balanis, NG; Carlin, CR; Pascuzzi, PE; Schiemann, BJ; Schiemann, WP; Wendt, MK; Williams, WK1
Chen, WD; Deng, R; Feng, GK; Ji, J; Jiao, L; Kong, PF; Li, X; Li, YT; Li, ZH; Qian, XJ; Wu, RY; Yu, Y; Zhu, XF1
Ashinuma, H; Sekine, I1
Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E1
Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H1
Printz, C1
Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL1
Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL1
Arteaga, CL; Li, L; Wang, H; Xia, F; Yang, ES1
Boyd, J; Brogi, E; Bromberg, JF; Caravelli, JF; D'Andrea, GM; Dancey, J; Dang, CT; Dickler, MN; Eberle, CA; Gilewski, TA; Hudis, CA; Lake, DE; Melisko, M; Moasser, MM; Norton, L; Panageas, KS; Park, JW; Rugo, HS; Seidman, AD; Yeh, B1
Anania, FA; Knight, BB; Merlin, D; O'Regan, RM; Saxena, NK; Sharma, D; Taliaferro-Smith, L1
Bosserman, LD; Britten, CD; Finn, RS; Lum, BL; Malik, M; Press, MF; Slamon, DJ; Wong, SG1
Hsu, JY; Wakelee, HA1
Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hung, MC; Krishnamurthy, S; LaFortune, TA; Liu, P; Lucci, A; Singh, B; Ueno, NT; Zhang, D1
Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY1
Dauendorffer, JN; Dupuy, A1
Gutteridge, E; Robertson, JF1
Ueno, NT; Yamauchi, H1
Ahmed, IS; Craven, RJ; Rohe, HJ; Twist, KE1
Wörmann, B1
Akar, U; Arun, BK; Hortobagyi, GN; LaFortune, TA; Nieves-Alicea, R; Tari, AM; Ueno, NT; Zhang, D1
Childs, BH; Pal, SK; Pegram, M1
Fridlyand, J; Fyfe, G; Kaiser, LD1
Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J1
Pandiella, A; Sánchez-Martín, M1
Bade, LK; Dehut, HA; Goldberg, JE; Hall, MK; Schwertfeger, KL1
Cortes, J; Roché, H1
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA1
Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M1
Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C1
Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G1
Eastman, BM; Gonias, SL; Jo, M; Takimoto, S; Webb, DL1
Al Saleh, S; Khajah, MA; Luqmani, YA; Mathew, PM1
Guirgis, HM1
Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A1
Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S1
Barbacci, EG; Boscoe, BP; Cox, ED; Emerson, E; Iwata, KK; Jani, JP; Kath, JC; Liu, Z; Miller, PE; Moyer, JD; Provoncha, K; Pustilnik, LR; Rossi, AM1
Figg, WD; Lepper, ER; Sparreboom, A; Swain, SM; Tan, AR1
Goldman, B1
Bacharach, SL; Berman, A; Brahim, JS; Carrasquillo, JA; Chow, C; Ettenberg, SA; Figg, WD; Hewitt, SM; Lepper, ER; Lipkowitz, S; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Whatley, M; Yang, X1
Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF1
Magné, N; Milano, G1
Gasparini, G; Longo, R; Morabito, A; Torino, F1
Friess, T; Hasmann, M; Scheuer, W1
Agrawal, A; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF1
Nguyen, D; Simon, RM; Swain, SM; Tan, AR; Yang, SX1
Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M1
Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH1
Chan, SK; Gullick, WJ; Hill, ME1
Adamoli, L; Catania, C; De Pas, TM; Goldhirsch, A; Manzotti, M; Nolè, F; Pelosi, G1
Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F1
Ben-Porat, L; Chapman, PB; Dickler, MN; Panageas, KS; Schrag, D1
Bartholomeusz, C; Hortobagyi, GN; Kurisu, K; Sudo, T; Ueno, NT; Yamasaki, F; Zhang, D1
Andersson, M; Nielsen, DL1
Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX1
Brown, KA; Emlet, DR; Kociban, DL; Ong, BB; Pollice, AA; Shackney, SE; Smith, CA1
Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F1
Adkins, TB; Arteaga, CL; Calvo, B; Frierson, KE; Granja, Nde M; Grau, AM; Guix, M; Kelley, MC; Krontiras, H; Krop, IE; Mayer, IA; Meszoely, I; Muthuswamy, S; Pestano, G; Sanchez, V; Sanders, ME; Shyr, Y; Wieman, BM1
Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T1
Belluco, C; Deng, J; Espina, V; Esserman, LJ; Laird, J; Liotta, LA; Mammano, E; Nitti, D; Petricoin, EF; Pierobon, M; Speer, R; Swain, SM; Wulfkuhle, JD; Yang, SX1
Haddad, TC; Yee, D1
Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP1
Fry, DW; Slichenmyer, WJ1

Reviews

13 review(s) available for erlotinib hydrochloride and Breast Neoplasms

ArticleYear
Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.
    Clinical breast cancer, 2018, Volume: 18, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Meningeal Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome

2018
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2009, Volume: 23, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A

2009
[Oncology 2010].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:25-26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome

2010
Triple negative breast cancer: unmet medical needs.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, BRCA2; Humans; Phenotype; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome

2011
Docetaxel combined with targeted therapies in metastatic breast cancer.
    Cancer treatment reviews, 2012, Volume: 38, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab

2012
Targeted therapies for cancer 2004.
    American journal of clinical pathology, 2004, Volume: 122, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab

2004
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
    Bulletin du cancer, 2004, Dec-01, Volume: 91 Suppl 4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab

2004
Therapy of breast cancer with molecular targeting agents.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine

2005
Overview of tyrosine kinase inhibitors in clinical breast cancer.
    Endocrine-related cancer, 2005, Volume: 12 Suppl 1

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2005
The role of the epidermal growth factor receptor in breast cancer.
    Journal of mammary gland biology and neoplasia, 2006, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2

2006
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab

2007
[Targeting ErbB receptors in breast cancer].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2007
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 16

    Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab

2001

Trials

8 trial(s) available for erlotinib hydrochloride and Breast Neoplasms

ArticleYear
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Nitrogen Mustard Compounds; Quinazolines; Severity of Illness Index

2013
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Middle Aged; Quinazolines; Treatment Outcome

2008
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
    Clinical breast cancer, 2009, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Tissue Distribution; Trastuzumab; Treatment Outcome

2009
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Clinical breast cancer, 2012, Volume: 12, Issue:3

    Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2

2012
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin

2008
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Tandem Mass Spectrometry; Treatment Outcome; Xenograft Model Antitumor Assays

2008
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome

2008
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
    Breast cancer research and treatment, 2009, Volume: 115, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids

2009

Other Studies

74 other study(ies) available for erlotinib hydrochloride and Breast Neoplasms

ArticleYear
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs).
    Genes, 2021, 10-23, Volume: 12, Issue:11

    Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Receptor Activator of Nuclear Factor-kappa B; Receptors, Estrogen

2021
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Drug design, development and therapy, 2022, Volume: 16

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles

2022
Protein tyrosine kinase 6 regulates activation of SRC kinase.
    The Journal of biological chemistry, 2022, Volume: 298, Issue:11

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Male; Mice; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; src-Family Kinases

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach.
    Breast cancer (Tokyo, Japan), 2023, Volume: 30, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; B7-H1 Antigen; Breast Neoplasms; CD8-Positive T-Lymphocytes; Drug Discovery; Erlotinib Hydrochloride; Female; Humans; Lymphocytes, Tumor-Infiltrating; Prognosis; T-Lymphocytes

2023
Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:4

    Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; PTEN Phosphohydrolase; Transcriptional Activation; Up-Regulation; Vorinostat

2023
CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
    Cells, 2020, 03-06, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; MCF-7 Cells; Phenylenediamines; Protein Kinase Inhibitors; Pyrimidines; Repressor Proteins; Survival Analysis; Trans-Activators; Triple Negative Breast Neoplasms

2020
Nevoid melanoma and eruptive nevi from erlotinib.
    Dermatology online journal, 2020, Jun-15, Volume: 26, Issue:6

    Topics: Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Melanoma; Nevus; Protein Kinase Inhibitors; Skin Neoplasms

2020
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Bioorganic & medicinal chemistry, 2020, 09-15, Volume: 28, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles

2020
Recurrent EGFR-Mutated Non-Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options.
    Oncology (Williston Park, N.Y.), 2020, Sep-15, Volume: 34, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mammography; Mutation; Ramucirumab; Surgical Procedures, Operative; Treatment Outcome

2020
Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
    Archiv der Pharmazie, 2021, Volume: 354, Issue:8

    Topics: A549 Cells; Antineoplastic Agents; Breast Neoplasms; Coumarins; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Solubility; Structure-Activity Relationship

2021
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:10

    Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab

2017
Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
    Biomaterials, 2017, Volume: 148

    Topics: Administration, Oral; Animals; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Immunotherapy; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Permeability; Tumor Microenvironment

2017
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
    Nature communications, 2017, 10-24, Volume: 8, Issue:1

    Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome

2017
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
    Journal of bioinformatics and computational biology, 2018, Volume: 16, Issue:3

    Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms

2018
Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast cancer research and treatment, 2019, Volume: 173, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mucin-2; RNA, Small Interfering; Xenograft Model Antitumor Assays

2019
AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 02-26, Volume: 116, Issue:9

    Topics: Adult; Amphiregulin; Animals; Apoptosis; BRCA1 Protein; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Mice; Middle Aged; Oxidation-Reduction; Reactive Oxygen Species; Receptors, Aryl Hydrocarbon; Tumor Microenvironment

2019
A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
    Journal of experimental & clinical cancer research : CR, 2019, May-22, Volume: 38, Issue:1

    Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Multiprotein Complexes; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Xenograft Model Antitumor Assays

2019
Predicting drug responsiveness in human cancers using genetically engineered mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment

2013
Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:11

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isotope Labeling; Neoplasm Proteins; Phosphopeptides; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tandem Mass Spectrometry; Tyrosine

2013
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
    International journal of oncology, 2014, Volume: 44, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines

2014
American Society of Clinical Oncology Annual Meeting 2013.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States

2013
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    International journal of cancer, 2014, May-15, Volume: 134, Issue:10

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms

2014
VAV3 mediates resistance to breast cancer endocrine therapy.
    Breast cancer research : BCR, 2014, May-28, Volume: 16, Issue:3

    Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles

2014
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    BMC systems biology, 2014, Jun-25, Volume: 8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Systems Biology; Time Factors

2014
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:3

    Topics: Adult; Breast Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult

2014
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:12

    Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines

2014
Metformin and erlotinib synergize to inhibit basal breast cancer.
    Oncotarget, 2014, Nov-15, Volume: 5, Issue:21

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Metformin; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
    Science signaling, 2014, Dec-09, Volume: 7, Issue:355

    Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Connective Tissue Growth Factor; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hippo Signaling Pathway; Humans; Lapatinib; Mechanotransduction, Cellular; Neuregulin-1; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-4; Transcription Factors

2014
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
    Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Metastasis; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Tumor Suppressor Proteins

2015
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy.
    Oncotarget, 2015, Jul-10, Volume: 6, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Cell Line, Tumor; DNA Damage; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; Lapatinib; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Transfection

2015
[Targeted therapy for solid tumors in the elderly].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab

2015
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Dec-01, Volume: 80

    Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles

2015
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Amino acids, 2016, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine

2016
Developments in precision medicine: Studies highlight new applications for cancer chemoprevention, treatment.
    Cancer, 2016, Mar-01, Volume: 122, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Humans; Loss of Heterozygosity; Mouth Neoplasms; Precancerous Conditions; Precision Medicine

2016
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
    Scientific reports, 2016, 06-08, Volume: 6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea

2016
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
    Oncotarget, 2016, Sep-27, Volume: 7, Issue:39

    Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases

2016
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
    Cancer research, 2008, Nov-15, Volume: 68, Issue:22

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromosome Breakage; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Genes, BRCA1; Histones; Humans; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; Recombination, Genetic

2008
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
    Cancer research, 2008, Dec-01, Volume: 68, Issue:23

    Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lapatinib; Leptin; Neoplasm Invasiveness; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Receptors, Leptin; Signal Transduction; Transcriptional Activation

2008
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-01, Volume: 15, Issue:21

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Lung Neoplasms; Male; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction

2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Nov-17, Volume: 106, Issue:46

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2009
Radiation recall dermatitis induced by erlotinib.
    Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:6

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis

2009
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
    Breast cancer research : BCR, 2009, Volume: 11 Suppl 3

    Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical

2009
Targeted therapy in inflammatory breast cancer.
    Cancer, 2010, Jun-01, Volume: 116, Issue:11 Suppl

    Topics: Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Quinazolines

2010
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
    The Journal of biological chemistry, 2010, Aug-06, Volume: 285, Issue:32

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochromes b5; Cytoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Membrane Proteins; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptors, Progesterone; RNA Interference

2010
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:11

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Silencing; Genes, erbB-1; Humans; Mice; Mice, Nude; Phosphorylation; Protein Binding; Protein Kinases; Quinazolines; RNA, Small Interfering; Serine; Stathmin; Xenograft Model Antitumor Assays

2010
Analysis of tumor burden versus progression-free survival for Phase II decision making.
    Contemporary clinical trials, 2011, Volume: 32, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden

2011
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
    Breast cancer research : BCR, 2011, Apr-15, Volume: 13, Issue:2

    Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome

2011
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
    International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1

    Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2012
Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
    Journal of cell science, 2011, Sep-15, Volume: 124, Issue:Pt 18

    Topics: Amphiregulin; Animals; Breast Neoplasms; Cell Growth Processes; Cell Line; Cell Movement; Cell Transformation, Neoplastic; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Mammary Glands, Human; MAP Kinase Signaling System; Mice; Mice, Transgenic; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1

2011
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:8

    Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline

2012
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Cellular signalling, 2012, Volume: 24, Issue:1

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation

2012
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
Pneumocystis jiroveci Pneumonia in an Atypical Host.
    Clinical breast cancer, 2012, Volume: 12, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination

2012
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
    Cellular signalling, 2012, Volume: 24, Issue:9

    Topics: Animals; Breast Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tumor Cells, Cultured

2012
Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokine CCL5; Chromones; Collagenases; Diphenylamine; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor I; Lymphokines; MCF-7 Cells; Morpholines; Phosphorylation; Platelet-Derived Growth Factor; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Estrogen; RNA, Small Interfering; Transforming Growth Factor beta

2012
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
    Journal of oncology practice, 2012, Volume: 8, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines

2012
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Oncotarget, 2012, Volume: 3, Issue:12

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays

2012
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
    Cancer science, 2013, Volume: 104, Issue:5

    Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome

2013
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
    Cancer research, 2003, Aug-01, Volume: 63, Issue:15

    Topics: 3T3 Cells; Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Enzyme Activation; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2003
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Oct-25, Volume: 796, Issue:1

    Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Quinazolines; Reproducibility of Results; Spectrophotometry, Ultraviolet

2003
For investigational targeted drugs, combination trials pose challenges.
    Journal of the National Cancer Institute, 2003, Dec-03, Volume: 95, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States

2003
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-01, Volume: 22, Issue:15

    Topics: Administration, Oral; Biomarkers; Breast Neoplasms; Endpoint Determination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mouth Mucosa; Neoplasm Metastasis; Phosphorylation; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin; Tomography, Emission-Computed

2004
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-15, Volume: 11, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured

2005
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen

2005
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays

2006
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model.
    Oncology reports, 2006, Volume: 16, Issue:1

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines

2006
Erlotinib-induced breast cancer regression.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:11

    Topics: Adult; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Radiography; Remission Induction

2006
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus

2006
When you look matters: the effect of assessment schedule on progression-free survival.
    Journal of the National Cancer Institute, 2007, Mar-21, Volume: 99, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Neoplasms; Population Surveillance; Quinazolines; Research Design; Statistics, Nonparametric; Time Factors

2007
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:8

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Genes, Dominant; Humans; Phosphorylation; Phosphotyrosine; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Transfection

2007
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase; Humans; Immunoblotting; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2007
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
    Journal of proteome research, 2008, Volume: 7, Issue:4

    Topics: Breast Neoplasms; Cluster Analysis; Erlotinib Hydrochloride; Female; Humans; Intracellular Signaling Peptides and Proteins; Lasers; Liver Neoplasms; Microdissection; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction

2008
Of mice and (wo)men: is this any way to test a new drug?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ki-67 Antigen; Mice; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2008